Abstract:In the year 2018, non-Hodgkin lymphoma constituted 2. 8% of the total number of cancer cases reported globally. [ 1 ] Non-Hodgkin lymphoma originates from lymph nodes or lymphocytes in extranodal tissues, and lymphoma of extranodal origin accounts for 25% to 30% of non-Hodgkin lymphomas. They most often involve the gastrointestinal tract and skin but can occur in rare sites such as the breast, adrenal gland, testis, and female genital tract. [ 2–5 ] Primary lymphoma of the female genital tract (PLFGT) accounts for 0.2% to 1.1% of all non-Hodgkin lymphomas, [ 6 ] and the National Cancer Database reports that only 1.5% of extranodal non-Hodgkin lymphomas originate from the female genital tract, including the ovaries, uterus, cervix, vagina and vulva. [ 7 ] Studies have shown that the ovaries are the most common site of female genital tract lymphoma, [ 8–10 ] but others have shown that cervix is the most common one. [ 11 ] R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is currently the chemotherapy regimen of choice for the treatment of cervical lymphoma. [ 12 , 13 ] although some patients undergo surgery, radiotherapy, and systemic therapy. [ 11–15 ]

Development and validation of nomograms to predict survival of primary cervical lymphoma: A surveillance, epidemiology, and end results (SEER) database analysis